Saturday, July 11, 2026

biotech · Advanced Solid Tumors · Seasonal Allergic Rhinitis · PRME

Prime Medicine

Prime Medicine is a biotech organization headquartered in Cambridge, USA. It trades on NYSE under ticker PRME. Primary therapeutic focus areas include Advanced Solid Tumors, Seasonal Allergic Rhinitis, Artificial Intelli

60 First St, Cambridge, Massachusetts 02141, US HQ
2019 Founded
185 Employees
Public company Type
PRME · NYSE Ticker
Company details
Status
Public
HQ
60 First St, Cambridge, Massachusetts 02141, US
Founded
2019
Employees
185
Programs
17
Drugs
6
Patents
127
Clinical program

PM359

Phase 2 · mab · Chronic Granulomatous Disease

PM359 for Chronic Granulomatous Disease is a Phase 2 program (mab) at Prime Medicine with 1 ClinicalTrials.gov record(s).

Internal code Prime-0101

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Prime Medicine
Phase
Phase 2
Modality
mab
Indication
Chronic Granulomatous Disease
Status
active
Trials
1

Clinical trials